secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVVITY, INC. (RVTY)
CIK:        0000031791
Form:       8-K
Filed at:   2021-09-10T23:59:59+00:00
Accession:  0001193125-21-269959
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PerkinElmer issues $2.3B in senior notes to finance BioLegend acquisition
-------------------------------------------------------------------------

- Issued $2.3B aggregate: $500M 0.55% notes due 2023, $800M 0.85% due 2024, $500M 1.90% due 2028, $500M 2.25% due 2031.
- Net proceeds ~$2.28B to partially fund $5.7B BioLegend acquisition announced July 25, 2021.
- Special mandatory redemption at 101% if BioLegend deal not closed by Jan 31, 2022.
- Bridge loan commitments reduced to $514M after net proceeds.
- Notes are general unsecured, rank equally with other unsecured debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/31791/000119312521269959/0001193125-21-269959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/31791/000119312521269959/d204305d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-269959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer